The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 22, 2020

Filed:

Aug. 04, 2017
Applicant:

Arrowhead Pharmaceuticals, Inc., Pasadena, CA (US);

Inventors:

Zhen Li, Madison, WI (US);

Rui Zhu, Madison, WI (US);

Christine Wooddell, Madison, WI (US);

Bruce D. Given, Madison, WI (US);

Tao Pei, Madison, WI (US);

David L. Lewis, Madison, WI (US);

Lauren J. Almeida, Madison, WI (US);

David B. Rozema, Cross Plains, WI (US);

Darren H. Wakefield, Fitchburg, WI (US);

Assignee:

ARROWHEAD PHARMACEUTICALS, INC., Pasadena, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); A61K 31/7105 (2006.01); A61P 31/14 (2006.01); A61K 9/00 (2006.01); A61K 31/675 (2006.01); A61P 31/20 (2006.01); A61K 31/7088 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7105 (2013.01); A61K 9/0019 (2013.01); A61K 31/675 (2013.01); A61K 31/7088 (2013.01); A61P 31/14 (2018.01); A61P 31/20 (2018.01); C12N 15/113 (2013.01); C12N 15/1131 (2013.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01); C12N 2310/314 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/322 (2013.01); C12N 2310/3515 (2013.01);
Abstract

Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) agents for inhibiting the expression of Hepatitis B virus gene are described. The HBV RNAi agents disclosed herein may be targeted to cells, such as hepatocytes, for example, by using conjugated targeting ligands. Pharmaceutical compositions comprising one or more HBV RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi agents to infected liver in vivo provides for inhibition of HBV gene expression and treatment of diseases and conditions associated with HBV infection.


Find Patent Forward Citations

Loading…